Mavericks Wanted

When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on

In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.

Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.

Position Summary

You are a fast, precise communications writer and operator who can help take a story from first draft to live – a press release on the wire, a disease awareness campaign across our channels, an all-company email in a leader's inbox. You know biotech news flow and the review gates every piece has to clear, and you know how to help make a rare disease visible to the people who need to recognize it, without crossing the promotional line. You're energized by the craft of execution – drafting, routing, scheduling, tracking – and you're eager to grow your scope as you learn the business.

The Senior Manager of Corporate Communications will support BridgeBio's corporate news flow, owned channels, disease awareness and education, and internal and executive communications. You will report to and work hand-in-hand with the Director of Communications, who sets direction and reviews and approves the work, while continuing to lead communications for regulatory milestones, launches, earnings, and financings. The team sits within Brand & Communications and you'll work daily with Patient Advocacy, Medical Affairs, Investor Relations, Legal, Regulatory, People, Marketing, and our agency partners.

This is a hands-on role with real room to grow. We want someone who takes initiative, spots gaps, brings ideas forward, and takes as much pride in distribution as in the narrative behind it. As you build expertise and trust, you'll take on increasing responsibility for workstreams within the function.

Why This Role Matters

BridgeBio's newsflow has never been heavier. We are issuing roughly a press release a week – data readouts, congress curtain raisers, clinical and regulatory milestones, earnings, and financings – while preparing for three more commercial launches on top of Attruby. Across our portfolio, many of the conditions we work in are underdiagnosed or misdiagnosed, which makes disease awareness and education some of the most important work we do. Our audience is growing quickly, and more teams across the company are asking Communications for help telling their stories. This role adds the capacity we need to sustain that pace with quality.

What You'll Do

Press Releases & Corporate Newsflow

Partner closely with Director of Communications, providing regular updates on in-flight work, flagging emerging issues and opportunities, and contributing ideas to communications planning across the team.
Draft recurring corporate press releases – congress curtain raisers, clinical milestones (e.g., first patient dosed), corporate announcements, etc. – for review by the Director of U.S. Communications, and support regulatory, earnings, and financing releases as needed
Support releases through BridgeBio's press release review protocol: route drafts to reviewers, consolidate comments, track approvals against deadlines, and QC every detail
Support the path from draft to distribution across our owned channel ecosystem, including proof review, wire and Nasdaq timing, IR email alerts, website posting, and partner notifications, in coordination with Investor Relations and BD